Clinical Research Directory
Browse clinical research sites, groups, and studies.
Communicating Multiple Uncertainties Associated With the Benefits and Risks of New Cancer Drugs
Sponsor: London School of Economics and Political Science
Summary
This nationally representative randomized survey of US adults will evaluate the effect of using brief statements to communicate multiple different sources of uncertainties about the benefits and harms of new cancer drugs on participants' decisions.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
3184
Start Date
2025-07-18
Completion Date
2025-07-26
Last Updated
2026-08-26
Healthy Volunteers
Yes
Conditions
Interventions
Statement communicating 1 source of uncertainty
It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova.
Statements communicating 2 sources of uncertainties
It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her.
Statements communicating 3 sources of uncertainties
It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live.
Statements communicating 4 sources of uncertainties
It is unknown whether patients with non-small cell lung cancer will notice an improvement with Zenova. Zenova has not been studied in patients similar to Alex (patients with her race and ethnicity). It is unknown whether Zenova will work and what harms it will have for patients like her. Zenova has only been shown to shrink the size of tumors. It is unknown whether Zenova improves how patients feel or how long they live. Since patients given Zenova were followed for a short time, the longer-term benefits and harms of taking Zenova are unknown.
Control group
No information about uncertainty
Locations (1)
London School of Economics and Political Science
London, United Kingdom